General Information of This Metabolic Reaction (MR) (ID:
MR001427) |
Formula |
|
Reactant |
Lapatinib ditosylate |
Product |
O-dealkylated lapatinib |
Reactant Info
|
Product Info
|
Metabolic Enzyme
|
Cytochrome P450 3A4 (CYP3A4)
|
DME Info
|
Cytochrome P450 2C8 (CYP2C8)
|
DME Info
|
Metabolic Type
|
Oxidation
-
O-Dealkylation
|
|
|
|
|
|
|
|
Other MR(s) Related to The Reactant of This MR |
Other MR(s) That Metabolize The Reactant of This MR
|
|
Other MR(s) Related to The Product of This MR |
Other MR(s) That Metabolize The Produtc of This MR
|
|
References |
1 |
Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib Drug Metab Dispos. 2011 Jun;39(6):1022-30. doi: 10.1124/dmd.110.037531.
|
2 |
Detoxication versus Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib Drug Metab Dispos. 2021 Mar;49(3):233-244. doi: 10.1124/dmd.120.000236.
|
3 |
Case Study 11: Considerations for Enzyme Mapping Experiments-Interaction Between the Aldehyde Oxidase Inhibitor Hydralazine and Glutathione. Methods Mol Biol. 2021;2342:809-823. doi: 10.1007/978-1-0716-1554-6_30.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.